Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Trementozzi

Pediatrics Ruther Glen, VA Medical Doctor

NPI 1821060047 CMS profile 1212365

18048 Jefferson Davis Hwy, Ruther Glen, VA 22546

Open in the dashboard

General payments

$2,457

132 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Trementozzi of Ruther Glen, VA is reported in the CMS Open Payments database as having received $2,457 across 132 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $512 25
2024 General $418 23
2023 General $477 25
2022 General $337 16
2021 General $207 13
2020 General $236 13
2019 General $269 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Trementozzi
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Daniel Trementozzi were reported at $512. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Daniel Trementozzi Pediatrics median Middle half National median
2019 $269 $86 $31–$183 $163
2020 $236 $49 $22–$110 $114
2021 $207 $68 $27–$158 $132
2022 $337 $77 $30–$173 $149
2023 $477 $88 $33–$190 $160
2024 $418 $94 $34–$206 $164
2025 $512 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $624 31 payments
  2. Amgen Inc. $292 15 payments
  3. Otsuka America Pharmaceutical, Inc. $222 11 payments
  4. Lilly USA, LLC $130 6 payments
  5. Pfizer Inc. $108 6 payments
  6. Merck Sharp & Dohme Corporation $106 7 payments
  7. Abbott Laboratories $96 4 payments
  8. GlaxoSmithKline, LLC. $94 6 payments
  9. AbbVie, Inc. $85 5 payments
  10. Cranial Technologies, Inc $79 6 payments
  11. Other $622 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,457 132 payments
Products named General payments · program years 2019–2025
  1. Ozempic $374 17 payments
  2. RYBELSUS $374 17 payments
  3. REXULTI $222 11 payments
  4. Repatha $199 10 payments
  5. Wegovy $183 10 payments
  6. GARDASIL 9 $106 7 payments
  7. VAXELIS $106 7 payments
  8. FreeStyle Libre 3 $96 4 payments
  9. JARDIANCE $95 4 payments
  10. PREVNAR 20 $93 5 payments
  11. Other $1,832 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

132 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record